| Literature DB >> 32274091 |
Ning Li1, Yu Zhang1, Yuan Gao1, Yifan Bai1, Fan Qiao1, Mengwei Tan1, Qingqi Han1, Fanglin Lu1, Bailing Li1, Lin Han1, Guanxin Zhang1, Zhiyun Xu1.
Abstract
BACKGROUND: Multiple of subsequent procedures may necessary in Marfan syndrome (MFS) patients after initial surgery. The aim of this study was to investigate the full spectrum of secondary distal vascular or valvular interventions encountered after initial surgery.Entities:
Keywords: Marfan syndrome (MFS); aneurysm; aortic dissection; aortic root replacement; mitral valve prolapse
Year: 2020 PMID: 32274091 PMCID: PMC7139013 DOI: 10.21037/jtd.2020.01.72
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 3.005
Baseline patient characteristics
| Variable | Aortic dissection, n=108 | Aneurysm, n=93 | P valve |
|---|---|---|---|
| Age, years | 37.3±11.5 | 36.6±14.3 | 0.687 |
| Female gender, n (%) | 40 (37.0) | 33 (35.5) | 0.819 |
| Weight, kg | 68.3±11.6 | 61.3±13.6 | <0.001 |
| Height, cm | 177.9±9.3 | 176.3±9.5 | 0.250 |
| Years of follow-up, years | 7.5±4.8 | 9.3±6.0 | 0.041 |
| BAV, n (%) | 2 (1.9) | 2 (2.2) | 1.000 |
| Hypertension, n (%) | 23 (21.3) | 14 (15.1) | 0.255 |
| Diabetes Mellitus, n (%) | 0 (0) | 2 (2.2) | 0.413 |
| Chronic kidney disease, n (%) | 0 (0) | 0 (0) | None |
| COPD, n (%) | 0 (0) | 0 (0) | None |
| Smoking, n (%) | 11 (10.2) | 16 (17.2) | 0.146 |
| Family history of AD, n (%) | 23 (21.3) | 11 (11.8) | 0.074 |
| CHD, n (%) | 0 (0) | 2 (2.2) | 0.413 |
| EF, % | 58.5±8.1 | 56.4±10.2 | 0.233 |
| Aortic regurgitation, n (%) | 0.801 | ||
| Severe | 74 (68.5) | 63 (67.7) | |
| Moderate | 6 (5.6) | 3 (3.2) | |
| None and mild | 28 (25.9) | 27 (29.0) | |
| Mitral regurgitation, n (%) | 0.093 | ||
| Severe | 6 (5.6) | 13 (14.0) | |
| Moderate | 8 (7.4) | 9 (9.7) | |
| None and mild | 94 (87.0) | 71 (76.3) | |
| Annulus diameter, cm | 2.56±0.32 | 2.88±0.36 | <0.001 |
| Ascending aorta diameter, cm | 5.39±1.40 | 5.99±1.64 | 0.007 |
| History of surgery, n (%) | |||
| TEVAR | 3 (2.8) | 3 (3.2) | 1.000 |
| MVP or MVR | 1 (0.9) | 1 (1.1) | 1.000 |
| NUSS | 0 (0) | 1 (1.1) | 0.281 |
| Preoperative medication, n (%) | |||
| ACEI | 12 (11.1) | 3 (3.2) | 0.064 |
| ARB | 3 (2.8) | 4 (4.3) | 0.840 |
| BB | 34 (31.5) | 13 (14.0) | 0.003 |
| CCB | 17 (15.7) | 9 (9.7) | 0.202 |
BAV, bicuspid aortic valve; COPD, chronic obstructive pulmonary diseases; AD, aortic dissection; CHD, coronary atherosclerosis heart disease; EF, ejection fraction; TEVAR, thoracic endovascular aortic repair; MVP, mitral valvuloplasty; MVR, mitral valve replacement; NUSS, pectus excavatum correction procedure; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, β-blocker; CCB, calcium channel blocker.
Operative data at the time of initial surgery
| Variables | Dissection, n=108 | Aneurysm, n=93 | P valve |
|---|---|---|---|
| Operative data, min | |||
| Cardiopulmonary bypass time | 166.1±48.6 | 121.2±40.1 | <0.001 |
| Cross-clamp time | 102.3±33.1 | 75.9±24.7 | <0.001 |
| DHCA time | 29.0±11.1a | 23.3±11.2b | 0.309 |
| DHCA temperature | 25.0±2.5a | 23.9 ±3.5b | 0.413 |
| Proximal repair, n (%) | 0.285 | ||
| Bentall | 100 (92.6) | 82 (88.2) | |
| VSRR | 8 (7.4) | 11 (11.8) | |
| Distal repair, n (%) | |||
| Total arch replacement | 74 (68.5) | 2 (2.2) | <0.001 |
| Hemi arch replacement | 9 (8.3) | 1 (1.1) | 0.042 |
| FET | 79 (73.1) | 3 (3.2) | <0.001 |
| Concomitant procedures, n (%) | |||
| MVP or MVR | 7 (6.5) | 17 (18.3) | 0.010 |
| CABG | 17 (15.7) | 3 (3.2) | 0.007 |
| TVP | 6 (5.6) | 9 (9.7) | 0.268 |
| ASDC | 0 (0) | 2 (2.2) | 0.127 |
| Operative mortality, n (%) | 11 (10.2) | 3 (3.2) | 0.098 |
| Operative complications, n (%) | |||
| Reexploration for bleeding | 7 (6.5) | 3 (3.2) | 0.463 |
| Mechanical ventilation time >72 h | 17 (15.7) | 9 (9.7) | 0.202 |
| Stroke and cerebral hemorrhage | 1 (0.9) | 0 (0) | 0.353 |
| Renal failure | 6 (5.6) | 3 (3.2) | 0.650 |
| Paralysis/paresis | 1 (0.9) | 0 (0) | 0.353 |
a, represents the data from the 83 patients who underwent arch replacement at initial surgery in dissection group. b, represents the data from the 3 patients who underwent arch replacement at initial surgery in aneurysm group. DHCA, deep hypothermic circulatory arrest; VSRR, valve-sparing root replacement; FET, frozen elephant trunk; MVP, mitral valvuloplasty; MVR, mitral valve replacement; CABG, coronary artery bypass grafting; TVP, tricuspid valvuloplasty; ASDC, atrial septal defect closure.
Figure 1Kaplan-Meier curves depicting freedom from end-point events in aneurysm group and dissection group. (A) End-point was secondary operation for aortic arch, the patients at risk were these failed to receive total arch replacement procedure at initial surgery. (B) End-point was distal aortic reoperation, including reoperation for aortic arch and descending aorta. (C) End-point was all-cause death. (D) End-point was mitral valve reoperation.
Multivariable analysis of risk factors for subsequent aortic operations
| Variable | Hazard ratio | P valve | 95% CI |
|---|---|---|---|
| Indication was aortic dissection | 0.255 | <0.001 | (0.119, 0.546) |
| Concomitant CABG | 1.172 | 0.721 | (0.489, 2.808) |
| Use of BB before initial surgery | 2.319 | 0.007 | (1.254, 4.288) |
| Weight <65 kg | 1.152 | 0.632 | (0.645, 2.059) |
| Age <30 years | 0.665 | 0.203 | (0.355, 1.246) |
CABG, coronary artery bypass grafting; BB, β-blocker.